Ana
Fernández Montes
![Foto de Ana](/img/nophoto.png)
![Foto de Hospital Universitario La Paz](/img/noimage_org.png)
Hospital Universitario La Paz
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario La Paz (22)
2024
-
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry
Gastric Cancer, Vol. 27, Núm. 1, pp. 131-145
-
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology
-
Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain
Clinical and Translational Oncology, Vol. 26, Núm. 4, pp. 864-871
2023
-
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089
-
Mental Adjustment, Functional Status, and Depression in Advanced Cancer Patients
International Journal of Environmental Research and Public Health, Vol. 20, Núm. 4
-
Psychological factors and prognostic communication preferences in advanced cancer: multicentre study
BMJ Supportive and Palliative Care, Vol. 13, Núm. e3, pp. E1342-E1350
-
Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study
Cancers, Vol. 15, Núm. 18
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
-
The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
Oncologist, Vol. 28, Núm. 10, pp. E902-E909
-
Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma
Cancer, Vol. 129, Núm. 16, pp. 2581-2592
2022
-
Dignity and psychosocial related variables in elderly advanced cancer patients
BMC Geriatrics, Vol. 22, Núm. 1
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
-
Identification of Thrombosis-Related Genes in Patients with Advanced Gastric Cancer: Data from AGAMENON-SEOM Registry
Biomedicines, Vol. 10, Núm. 1
-
SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021)
Clinical and Translational Oncology, Vol. 24, Núm. 4, pp. 658-669
-
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
ESMO Open, Vol. 7, Núm. 3
2021
-
Ascertaining breast cancer patient experiences through a journey map: A qualitative study protocol
PLoS ONE, Vol. 15, Núm. 12 December
-
Breast cancer patient experiences through a journey map: A qualitative study
PLoS ONE, Vol. 16, Núm. 9 September
-
Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
Cancer Chemotherapy and Pharmacology, Vol. 87, Núm. 4, pp. 543-553
-
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 988-1000
2020
-
Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry
Clinical and Translational Oncology, Vol. 22, Núm. 5, pp. 734-750